Capsule Summary Slidesets

Share

Program Content

Activities

  • ARAMIS QoL
    Phase III ARAMIS Trial: Quality-of-Life Outcomes With Darolutamide + ADT vs Placebo + ADT in Patients With Nonmetastatic Castrate-Resistant Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2019

    Expires: May 31, 2020

  • ENZAMET: Enzalutamide in mHSPC
    ENZAMET: Phase III Trial of SoC Therapy With or Without Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2019

    Expires: June 04, 2020

  • TITAN: Apalutamide for mCSPC
    TITAN: Phase III Trial of Apalutamide vs Placebo in Patients With Metastatic Castration-Sensitive Prostate Cancer Receiving ADT
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2019

    Expires: June 05, 2020

  • EV-201: Enfortumab vedotin in UC
    EV-201: Enfortumab Vedotin in Advanced Urothelial Cancer Previously Treated With Platinum Chemotherapy and Immune Checkpoint Inhibitors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2019

    Expires: June 05, 2020

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro